Hygromycin B therapy of a murine coronaviral hepatitis.
Hepatitis caused by mouse hepatitis virus (MHV-A59), a murine coronavirus, is accompanied by direct infection and replication of virus within the liver. We demonstrate here that the aminoglycoside hygromycin B is able to eliminate MHV-A59 infection from mouse peritoneal macrophages and cultured liver cells in vitro and is also able to reduce levels of virus replication and necrotic liver foci in vivo.
Macintyre
G
G
Department of Microbiology and Infectious Diseases, University of Calgary, Alberta, Canada.
Curry
B
B
Wong
F
F
Anderson
R
R
D000818:Animals; D002470:Cell Survival / Q000187:drug effects; D002478:Cells, Cultured; D005455:Fluorescent Antibody Technique; D006524:Hepatitis, Viral, Animal / Q000188:drug therapy* / Q000382:microbiology; D006921:Hygromycin B / Q000627:therapeutic use* / Q000633:toxicity; D008099:Liver / Q000382:microbiology; D008264:Macrophages / Q000187:drug effects / Q000382:microbiology; D051379:Mice; D008805:Mice, Inbred A; D008807:Mice, Inbred BALB C; D006517:Murine hepatitis virus; D014779:Virus Replication / Q000187:drug effects
D006921:Hygromycin B